In in vitro studies, GM-CSF has been shown to reverse sepsis-induced monocyte hyporesponsiveness by normalizing monocyte HLA-DR expression and subsequently improving pathogen antigen presentation to adaptive immune response cells to restore immunocompetence (171, 172). This evidence concerns the gene CSF2 and Sepsis.